Mark Hamilton, MD, PhD, on Analyzing PostCAR Myeloid Neoplasms
The hematology-oncology and BMT cell therapy fellow at Stanford University discussed implications of his institution’s findings on treatment-related secondary malignancies.
“One question that we're often asked is whether we should avoid therapy in patients with clonal hematopoiesis mutations, since they can be detected. We don't see any evidence, at least so far, that patients with lymphoma should be denied a life-saving therapy because they have the presence of these mutations prior to infusion. Of course, more work is certainly needed to better define and understand these processes, but as of right now, we find that they're kind of what we would expect.”
In early 2024, the FDA began requiring black box warnings for all chimeric antigen receptor T-cell (CAR-T) therapy products that had been approved by the agency at that time.1 The warnings were related to the potential risk for the development of secondary T-cell malignancies occurring in relation to treatment with BCMA- and CD19-directed genetically modified autologous CAR-T therapy.
In light of these warnings, interest has continued in gaining a better understanding a better understanding of these risks, including the mechanisms behind them and their similarity to other treatment-related risks in oncology. One such study on this topic was presented at at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, held December 7-10, 2024, in San Diego, California, by Mark Hamilton, MD, PhD, a hematology-oncology and bone marrow transplant (BMT) cell therapy fellow at Stanford University.2 The single-institution study evaluated data from a cohort of patients treated with CAR-T therapy for nonHodgkin lymphoma (NHL) at Stanford University.
In an interview with CGTLive® held shortly after the conference, Hamilton described the key results of the study and their implications. He pointed out that postCAR myeloid neoplasms seem to derive from preexisting clonal hematopoeisis and occur in patients with high treatment burdens that often have TP53 mutations. Hamilton also discussed some of the challenges and limitations of the study, and emphasized that more research on this topic is needed.
For more coverage of ASH 2024, click here.
